National position
From 23 June 2025, people who meet the initial qualifying criteria (a BMI of at least 40 and four of the five stated weight related comorbidities), will be eligible via primary care, if both patient and clinician agree it is the most appropriate treatment option.
Full qualifying criteria is a BMI (Body Mass Index) of 40 plus* and four or more of the following diagnosed health conditions:
✓ type 2 diabetes
✓ high blood pressure
✓ heart disease
✓ obstructive sleep apnoea
✓ abnormal blood fats (dyslipidaemia).
(* We use a lower BMI threshold – usually reduced by 2.5 kg/m2 – for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds)
Appointments to discuss the starting of this medication will not be offered to patients unless they meet the above criteria.
Access to the medication goes hand in hand with behavioural support and wraparound care. Those who gain access to tirzepatide (Mounjaro®) on the NHS must also be referred onto a diet and exercise support programme.
The structured wraparound care support focuses on good nutrition to support health and increasing physical activity.
This support is designed specifically for people receiving tirzepatide (Mounjaro®) to help them get the most out of their treatment and enhance their ability to achieve and maintain healthy weight loss.
If you have any queries, please visit the DD ICB website: https://joinedupcarederbyshire.co.uk/stay-well/tirzepatide/
Local services are available for patients via:
– Livewell: https://livewellderby.co.uk/
– Live Life Better: https://www.livelifebetterderbyshire.org.uk/home.aspx
National schemes are also available including:
– the NHS Digital Weight Management Programme
– NHS Type 2 Diabetes Path to Remission Programme
– the NHS Diabetes Prevention Programme
which are a few of many existing NHS services.
Thank you.